HELP logo

CYBIN INC

HELPNASDAQ
🏆 #2637 by market capEarnings Nov 11US Equity
$363.86▼ $13.03 (−3.58%)
Simulated price
🔔
Track HELP
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$797M
Small Cap
📈Revenue Growth (YoY)
-9561.6%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair
No chart data available for HELP.

Trading Snapshot

Day Range
$361.92 – $368.43
52-Week Range
$3.76 – $15.15
Volume
$3.19B
Avg Volume
$4.13B
Shares Outstanding
62.0M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$163M
Last Q Revenue
$42M
P/E Ratio
-3.1
P/S Ratio
0.0x
EPS (TTM)
$-3.35
Dividend Yield
0.00%
Dilution (1yr)
+116.1%

Why Investors Own HELP

  • ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 77% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HELP logo

CYBIN INC

HELP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
−$45M▼ −9561.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.3%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$142M▼ −1.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$134M▲ +29.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
52.3M▲ +116.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$166M▼ −$29M YoY
StockOtter · stockotter.space

About CYBIN INC

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$362.41
▼ −0.4% Downside
High Target$440.17
Low Target$271.67
Based on 37 analysts

Latest News & Updates

🚀
Reuters·2h ago

CYBIN INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift HELP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

CYBIN INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.